BRPI0907907A2 - Método para inibir ou trata câncer de bexiga superficial em um mamífero, e, uso de um agonista de tlr 7 - Google Patents

Método para inibir ou trata câncer de bexiga superficial em um mamífero, e, uso de um agonista de tlr 7

Info

Publication number
BRPI0907907A2
BRPI0907907A2 BRPI0907907-6A BRPI0907907A BRPI0907907A2 BR PI0907907 A2 BRPI0907907 A2 BR PI0907907A2 BR PI0907907 A BRPI0907907 A BR PI0907907A BR PI0907907 A2 BRPI0907907 A2 BR PI0907907A2
Authority
BR
Brazil
Prior art keywords
mammal
inhibit
bladder cancer
tlr agonist
superficial bladder
Prior art date
Application number
BRPI0907907-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Dennis A Carson
Lorenzo M Leoni
Original Assignee
Univ California
Telormedix S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Telormedix S A filed Critical Univ California
Publication of BRPI0907907A2 publication Critical patent/BRPI0907907A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0907907-6A 2008-02-07 2009-02-06 Método para inibir ou trata câncer de bexiga superficial em um mamífero, e, uso de um agonista de tlr 7 BRPI0907907A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2699908P 2008-02-07 2008-02-07
PCT/US2009/000771 WO2009099650A2 (en) 2008-02-07 2009-02-06 Treatment of bladder diseases with a tlr7 activator

Publications (1)

Publication Number Publication Date
BRPI0907907A2 true BRPI0907907A2 (pt) 2015-07-28

Family

ID=40939077

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907907-6A BRPI0907907A2 (pt) 2008-02-07 2009-02-06 Método para inibir ou trata câncer de bexiga superficial em um mamífero, e, uso de um agonista de tlr 7

Country Status (12)

Country Link
US (1) US20090202626A1 (cg-RX-API-DMAC10.html)
EP (1) EP2259788A4 (cg-RX-API-DMAC10.html)
JP (2) JP2011511073A (cg-RX-API-DMAC10.html)
KR (1) KR20100137449A (cg-RX-API-DMAC10.html)
CN (1) CN102088974A (cg-RX-API-DMAC10.html)
AU (1) AU2009210655B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0907907A2 (cg-RX-API-DMAC10.html)
CA (1) CA2713438A1 (cg-RX-API-DMAC10.html)
EA (1) EA201001264A1 (cg-RX-API-DMAC10.html)
IL (1) IL207246A0 (cg-RX-API-DMAC10.html)
MX (1) MX2010008697A (cg-RX-API-DMAC10.html)
WO (1) WO2009099650A2 (cg-RX-API-DMAC10.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2620182A1 (en) * 2005-08-22 2007-03-01 Dennis A. Carson Tlr agonists
US8846697B2 (en) 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
EP2510946B1 (en) 2007-02-07 2015-08-05 The Regents of The University of California Conjugates of synthetic tlr agonists and uses therefor
WO2010020590A1 (en) * 2008-08-20 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the response to anti-cancer treatment with an agonist of tlr7 or an agonist of tlr8
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
WO2012038058A1 (en) 2010-09-21 2012-03-29 Telormedix Sa Treatment of conditions by toll-like receptor modulators
KR101250419B1 (ko) 2010-12-16 2013-04-05 강원대학교산학협력단 Ｔｌｒ 작동제를 포함하는 유방암 방사선 치료 보조제
ES2691745T3 (es) 2011-04-08 2018-11-28 Janssen Sciences Ireland Uc Derivados de pirimidina para el tratamiento de infecciones víricas
DK2776439T3 (en) 2011-11-09 2018-10-22 Janssen Sciences Ireland Uc PURINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
EA039373B1 (ru) * 2012-02-08 2022-01-19 Янссен Сайенсиз Айрлэнд Юси Производные пиперидино-пиримидина для лечения вирусных инфекций
DK2872515T3 (en) 2012-07-13 2016-09-19 Janssen Sciences Ireland Uc MACROCYCLIC PURINES FOR TREATING VIRUS INFECTIONS
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
MX386924B (es) 2012-10-10 2025-03-19 Janssen Sciences Ireland Uc Derivados pirrolo[3,2-d]pirimidínicos para el tratamiento de infecciones víricas y otras enfermedades.
US9663474B2 (en) 2012-11-16 2017-05-30 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections
KR102300861B1 (ko) 2013-02-21 2021-09-10 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
WO2014154859A1 (en) 2013-03-29 2014-10-02 Janssen R&D Ireland Macrocyclic deaza-purinones for the treatment of viral infections
UA117586C2 (uk) 2013-05-24 2018-08-27 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Похідні піридину для лікування вірусних інфекцій та інших захворювань
MX392130B (es) 2013-06-27 2025-03-21 Janssen Sciences Ireland Uc Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades.
ES2836881T3 (es) 2013-07-30 2021-06-28 Janssen Sciences Ireland Unlimited Co Derivados de tieno[3,2-d]pirimidinas para el tratamiento de infecciones virales
EP3092256B1 (en) 2014-01-10 2022-05-18 Birdie Biopharmaceuticals Inc. Compounds and compositions for immunotherapy
WO2015104030A1 (en) * 2014-01-10 2015-07-16 Telormedix Sa Pharmaceutical compositions comprising imiquimod for use in the treatment of carcinoma in situ of the bladder
EP3659603A1 (en) * 2014-01-10 2020-06-03 Urogen Pharma Ltd. Pharmaceutical compositions comprising imiquimod for use in the treatment of carcinoma in situ of the bladder
DK4001311T3 (da) 2014-07-09 2026-02-02 Birdie Biopharmaceuticals Inc Anti-pd-l1/pd-1-kombinationer til behandling af tumorer
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
KR101729236B1 (ko) 2015-06-01 2017-04-21 (주)노터스생명과학 Tlr7 항진제를 포함하는 비만 또는 간질환 예방 및 치료용 약학 조성물
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-her2组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
MA45539A (fr) 2016-07-01 2019-05-08 Janssen Sciences Ireland Unlimited Co Dihydropyranopyrimidines pour le traitement d'infections virales
SG10202010317VA (en) 2016-09-29 2020-11-27 Janssen Sciences Ireland Unlimited Co Pyrimidine prodrugs for the treatment of viral infections and further diseases
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
FI3641771T3 (fi) * 2017-06-23 2026-08-11 Birdie Biopharmaceuticals Inc Farmaseuttisia koostumuksia
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
US12702790B2 (en) 2019-06-13 2026-08-11 Hollister Incorporated Reusable urinary catheter kits
LT3952973T (lt) 2019-06-13 2023-07-10 Hollister Incorporated Daugkartinio naudojimo šlapimo kateterio produktai
WO2020263859A1 (en) 2019-06-25 2020-12-30 Hollister Incorporated Reusable urinary catheter products
CN112778372B (zh) * 2019-11-11 2025-09-23 苏州泽璟生物制药股份有限公司 咪唑并喹啉取代磷酸酯类激动剂及其制备方法和应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5736553A (en) * 1988-12-15 1998-04-07 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5037986A (en) * 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
NZ232740A (en) * 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
DK0553202T3 (da) * 1990-10-05 1995-07-03 Minnesota Mining & Mfg Fremgangsmåde til fremstilling af imidazo(4,5-c)quinolin-4-aminer
US5175296A (en) * 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5648516A (en) * 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19505168A1 (de) * 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US5693811A (en) * 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
DE19637209B4 (de) * 1996-09-12 2006-12-14 Siemens Ag Verfahren zum Steuern des Antriebsstrangs eines Kraftfahrzeugs und integrierte Antriebsstrangsteuerung
JP4391592B2 (ja) * 1996-10-25 2009-12-24 スリーエム カンパニー Ｔｈ２介在性および関連疾患治療のための免疫応答修飾化合物
DE69824632T2 (de) * 1997-11-12 2005-06-09 Mitsubishi Chemical Corp. Purinderivate und medikamente, welche dieselben als aktiven bestandteil enthalten
JP4375901B2 (ja) * 1997-11-28 2009-12-02 大日本住友製薬株式会社 新規な複素環化合物
US7001609B1 (en) * 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
PL349773A1 (en) * 1999-01-08 2002-09-09 3M Innovative Properties Co Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions
US6486168B1 (en) * 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US20030187261A1 (en) * 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
US6533645B2 (en) * 2000-01-18 2003-03-18 Applied Materials, Inc. Substrate polishing article
US6733764B2 (en) * 2000-06-14 2004-05-11 Alain Martin Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer
US20040023211A1 (en) * 2000-09-15 2004-02-05 Kees Groen System and method for optimizing drug theraphy for the treatment of diseases
AU2002211602A1 (en) * 2000-10-11 2002-04-22 Johns Hopkins University Polymer controlled delivery of a therapeutic agent
US20020127224A1 (en) * 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
WO2002081443A1 (en) * 2001-04-09 2002-10-17 Chiron Corporation Novel guanidino compounds
JP4331944B2 (ja) * 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
ATE307132T1 (de) * 2001-06-29 2005-11-15 Cv Therapeutics Inc Purin derivate als a2b adenosin rezeptor antagonisten
EP1440072A4 (en) * 2001-10-30 2005-02-02 Conforma Therapeutic Corp PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY
CA2497765A1 (en) * 2002-09-27 2004-04-08 Sumitomo Pharmaceuticals Co., Ltd. 8-hydroxy substituted adenine compounds and uses thereof
EP1608384A2 (en) * 2003-01-28 2005-12-28 Shanghai Sunway Biotech Co Ltd Therapy for primary and metastatic cancers
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
WO2005016235A2 (en) * 2003-04-14 2005-02-24 The Regents Of The University Of California Combined use of impdh inhibitors with toll-like receptor agonists
US20050059613A1 (en) * 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
WO2005020892A2 (en) * 2003-08-08 2005-03-10 Mitochroma Research, Inc. Pharmaceutical compositions and methods for metabolic modulation
EP1667694B1 (en) * 2003-09-05 2010-04-28 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
NZ546611A (en) * 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
FR2863890B1 (fr) * 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
JP2007526322A (ja) * 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
BRPI0509258A8 (pt) * 2004-03-26 2019-01-22 Astrazeneca Ab composto de 8-oxoadenina 9-substituída
WO2006054129A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
WO2006065234A1 (en) * 2004-12-10 2006-06-22 University Of Pittsburgh Use of lipid and hydrogel vehicles for treatment and drug delivery
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
CA2620182A1 (en) * 2005-08-22 2007-03-01 Dennis A. Carson Tlr agonists
WO2007034917A1 (ja) * 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規なアデニン化合物
EP1939202A4 (en) * 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
US20070100146A1 (en) * 2005-11-03 2007-05-03 Trevor Dzwiniel Process for the preparation of imidazo[4,5-c]-quinolin-4-amines
US8846697B2 (en) * 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
US8338593B2 (en) * 2006-07-07 2012-12-25 Gilead Sciences, Inc. Modulators of toll-like receptor 7
TW200831104A (en) * 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
EP2510946B1 (en) * 2007-02-07 2015-08-05 The Regents of The University of California Conjugates of synthetic tlr agonists and uses therefor
EP2170888B1 (en) * 2007-06-29 2015-04-22 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
JP2011500716A (ja) * 2007-10-16 2011-01-06 ギリアード・パロ・アルト・インコーポレイテッド Ａ３アデノシン受容体アンタゴニスト
KR20110117705A (ko) * 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
BR112012009329A2 (pt) * 2009-10-22 2016-06-07 Gilead Sciences Inc derivados de purina ou deazapurina úteis para o tratamento de infecções virais (inter alia)
EP2563404B1 (en) * 2010-04-30 2016-09-21 Urogen Pharma Ltd. Phospholipid drug analogs
WO2011134669A1 (en) * 2010-04-30 2011-11-03 Telormedix Sa Methods for inducing an immune response
JP2013538217A (ja) * 2010-09-01 2013-10-10 ノバルティス アーゲー 不溶性金属塩への免疫増強物質の吸着
WO2012038058A1 (en) * 2010-09-21 2012-03-29 Telormedix Sa Treatment of conditions by toll-like receptor modulators

Also Published As

Publication number Publication date
WO2009099650A4 (en) 2010-01-14
JP2014129425A (ja) 2014-07-10
CA2713438A1 (en) 2009-08-13
MX2010008697A (es) 2010-12-07
AU2009210655A1 (en) 2009-08-13
WO2009099650A3 (en) 2009-10-22
JP2011511073A (ja) 2011-04-07
AU2009210655B2 (en) 2013-08-15
WO2009099650A2 (en) 2009-08-13
EP2259788A2 (en) 2010-12-15
CN102088974A (zh) 2011-06-08
US20090202626A1 (en) 2009-08-13
EP2259788A4 (en) 2011-03-16
KR20100137449A (ko) 2010-12-30
IL207246A0 (en) 2010-12-30
EA201001264A1 (ru) 2011-04-29

Similar Documents

Publication Publication Date Title
BRPI0916630A2 (pt) composições para uso em construção e processo de aplicação das mesmas
BRPI0818963A2 (pt) Conjugado anticorpo-molécula parceira e método para tratar câncer em um indivíduo
BRPI1009381A2 (pt) compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica
BRPI0923442A2 (pt) polipeptídeos solúveis para uso em tratamento de distúrbio autoimunes e inflamatórios.
BRPI0911426A2 (pt) ferramentas terapêuticas e métodos para tratar cegueira
BR112012013247A2 (pt) conjunto submarino e método para uso em operações submarinas"
BR112012000417A2 (pt) aparelho para uso em tratamento terapêutico e/ou cosmético
BRPI0910433A2 (pt) composição de polímero responsivo a estímulos de auto-estabelecimento em aditivos para o solo e métodos para o uso
BRPI0910955A2 (pt) método para suavizar o uso não autorizado de um dispositivo
BRPI0916536A2 (pt) bainha para uso em conjunto com um artigo para fumar
BRPI0911297A2 (pt) composição e métodos para preparo e uso das mesmas
BRPI0914007A2 (pt) anatagonistas e agentes de ligação de notch e métodos para uso dos mesmos
BRPI0913710A2 (pt) "artigo e métodos para preparação do artigo"
BRPI0917711A2 (pt) método para avaliar o estado renal em um paciente, e, uso de um ou mais marcadores de lesão renal
BRPI0921726A2 (pt) método e dispositivo para ativar células tronco
BR112013012669A2 (pt) válvula de segurança para uso em um poço subterrâneo e ferramenta de poço
BR112012008854A2 (pt) combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano
BRPI0906683A2 (pt) método para medir e caracterizar microvesículas em fluidos corporais humanos
BRPI0816382A2 (pt) Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças
BRPI0908177A2 (pt) compósito elástico e método para produzir o mesmo
BRPI0810806A2 (pt) Método para tratar uma lesão cutânea em um indivíduo
BRPI0906692A2 (pt) Fluidos de furo de poço baseados em tensoativo viscoelástico e métodos de uso
BRPI0911925A2 (pt) método para detectar um câncer e regentes para detectar um câncer
BR112014010162A2 (pt) uso de composição, método para melhorar o reconhecimento e/ou tratar ou prevenir função de reconhecimento prejudicada em um indivíduo, e composição
BRPI1015233A2 (pt) métodos para tratar ou prevenir a fadiga

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]